dr. Daisy Flamez (PhD)
Coordinator of the BIOMARKED consortium at Ghent University (since 2010).
Coordinator of the UGent CRIG Business Unit at Ghent University (since august 2016).
I strongly believe that bringing together multidisciplinary expertise is key for the realization of top cancer research, but working synergistic with multidisciplinary expertise at the level of business development and building a strong industrial network helps to bring faster innovative results to the market and to the patients worldwide.
Passionate towards innovation in applied biomarker research.
Daisy Flamez holds a PhD in Sciences - specialization tumor immunotherapy – obtained Walter Fiers lab, one of the pioneers of the VIB. After > 15 years of postdoctoral experience in diabetes research in an international setting, she returned to Ugent and has > 10 years business development expertise.
At UGent she heads BIOMARKED, the business unit focused on pre-clinical applied biomarker research and facilitates innovation towards novel diagnostic tests, gene therapy, biologic therapeutics or spinning out platform expertise. She is an experienced business manager supporting academic researchers in translating science to innovation opportunities for Pharma/Biotech. She facilitated the setup/management of numerous (inter)national bilateral R&D collaborations and the setup of the Centers of Excellence such as NXTGNT and the Cancer Research Institute Ghent (CRIG). She realized > 15 license and option contracts and facilitated 4 spin-out companies.
Biomarker pre-clinical research towards diagnostics and gene therapy/RNA abled targeted therapies, oncology, diabetes, HIV and ageing diseases such as Cataract and dryAMD, business development and contract management, network/partnering with industrial partners, patent portfolio management, facilitation of obtaining (inter)national innovation funds, licensing and venturing.